J&J’s Spravato Gets EU Okay For Drug-Resistant Depression
Nasal Spray Completes Approval Process Unscathed
Concerns that written interventions might delay the expected EU approval of the novel ketamine-based antidepressant have come to naught.
You may also be interested in...
The EMA has received written interventions from third parties relating to its CHMP opinion that the controversial antidepressant should receive EU approval.
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.
Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking abstracts that are due to presented, including therapies from AbbVie, Gilead Sciences, Pfizer, Takeda, Amgen, AstraZeneca and Daiichi Sankyo.